Russ Conroy

Findings from an open-label trial support the FDA approval of inotuzumab ozogamicin as a treatment for pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Investigators are evaluating IO-202 in patients with newly diagnosed chronic myelomonocytic leukemia as part of a phase 1 dose expansion trial.

Investigators are assessing avutometinib plus defactinib as a treatment for those with low-grade serous ovarian cancer as part of the phase 3 RAMP 301 trial.

Investigators will assess A2B530 as a treatment for patients with germline heterozygous HLA-A*02–positive colorectal cancer expressing carcinoembryonic antigen in the phase 1/2 EVEREST-1 trial.

Findings suggest that harnessing the tumoral node microenvironment may improve the ability to predict extracapsular nodal extensions in patients with oropharyngeal carcinoma.

Data from the phase 3 RUBY trial support the recommendation for dostarlimab plus chemotherapy for patients with advanced MSI-H/dMMR endometrial cancer.

Data from the TROPION-Lung01 and TROPION-Breast01 trials support the EU marketing authorization applications for datopotamab deruxtecan in non–small cell lung cancer and breast cancer, respectively.

The role of multimodal approaches such as FDG-PET imaging may require further investigation in patients with human papillomavirus–positive oropharyngeal cancer, according to Samuel Regan, MD.

The regulatory agency has cleared developers to continue patient enrollment in the phase 2 IOV-LUN-202 trial evaluating LN-145 in non–small cell lung cancer.

Noa Biran, MD, speaks about recently approved bispecific therapies and current trials that may impact the standard of care in relapsed/refractory multiple myeloma.

Panitumumab plus modified FOLFOX6 appears to increase survival among patients with metastatic colorectal cancer and circulating tumor DNA that has no gene alterations in the PARADIGM trial.

Higher CA19-9 levels appear to correlate with increased recurrence and mortality for specific patients with pancreatic cancer who undergo surgical resection.

Frontline pembrolizumab with or without chemotherapy appears to remain a standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma based on data from the LEAP-010 study.

Data from the phase 3 PAPILLON trial support the FDA approval of amivantamab plus chemotherapy for patients with metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

Findings from the phase 3 DeFi trial support the marketing authorization application for nirogacestat as a treatment for adult patients with desmoid tumors in the European Union.

The nivolumab with chemotherapy regimen missed the primary end point on the phase 3 trial of patients with EGFR-mutated non–small cell lung cancer.

Findings from the phase 3 OCEAN trial did not confirm the clinical benefit of melphalan flufenamide as a treatment for patients with relapsed/refractory multiple myeloma.

Data from the phase 1 portion of the ARROS-1 trial support the breakthrough therapy designation for NVL-520 as a treatment for those with ROS1-positive non–small cell lung cancer.

ABCA12, CLIP1, and ATP13A3 somatic mutations appear to correlate with a vascular invasion phenotype in patients with poorly differentiated thyroid cancer.

Data from the phase 1/2 EPCORE NHL-1 trial support the supplemental biologics license application for epcoritamab as a treatment for patients with relapsed/refractory follicular lymphoma.

Data from the phase 3 RATIONALE 305 trial support the biologics license application for tislelizumab plus chemotherapy in advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Findings from 3 phase 3 trials support the marketing authorization application for tislelizumab as a treatment for patients with non–small cell lung cancer in the European Union.

Emphasizing precise terminology in clinical studies may improve the transparency and accuracy of information presented at oncology conferences.

Preliminary findings from a phase 1 trial support the breakthrough therapy designation for BAY 2927088 as a treatment for those with unresectable or metastatic non–small cell lung cancer harboring HER2 mutations.

The European Medicine Agency’s Committee for Medicinal Products for Human Use’s recommendation of approving pembrolizumab plus chemotherapy in resectable non–small cell lung cancer is based on results from the KEYNOTE-671 trial.

Investigators are currently evaluating treatment with IMM-1-104 in pancreatic cancer and other disease types associated with the RAS pathway as part of a phase 1/2a study.

Findings from a retrospective study demonstrate the feasibility of using brexucabtagene autoleucel to treat patients with relapsed/refractory B-cell acute lymphoblastic leukemia with central nervous system involvement.

Data from the phase 1/2 LINKER-MM1 trial support the biologics license application for linvoseltamab as a treatment for patients with relapsed/refractory multiple myeloma.

The FDA has set a Prescription Drug User Fee Act date of June 21, 2024 for adagrasib plus cetuximab as a treatment for patients with previously treated KRAS G12C-mutated colorectal cancer.

Patients with relapsed/refractory multiple myeloma can now receive teclistamab at 1.5 mg/kg every 2 weeks following the FDA’s latest approval.